
Opinion|Videos|December 23, 2024
Patient Education: Preparing Patients for ALK Inhibitor Treatment
Medical experts discuss strategies for patient education on managing potential adverse events of lorlatinib and other ALK inhibitors, emphasizing what to expect and when to contact the care team.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you approach patient education regarding potential adverse events associated with lorlatinib and other ALK inhibitors? What do you tell patients to expect and about when to contact their care team?
Advertisement
Related to this article

As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.

A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.

Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.

Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.

Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.

At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.

Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Daraxonrasib and RAS Inhibition: What Oncology Nurses Need to Know
2
October 2026 FDA Approvals: 7 Cancer Updates for Oncology Nurses
3
Childhood Leukemia Treatment Disrupts Work, Finances for Most Families
4
Education, Infection Vigilance Define Outpatient Bispecific Care
5

